Viewing nowPregabalin Tablets 75 mg (Pregabalin)
Pregabalin 75mg
Tablet · Prescription medication
Korean United Pharmaceutical Co., Ltd.

MFDS item code 202003059 · Approved 2020.04.27 · Insurance code 644309480
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, with or without secondary generalization, and aids in alleviating the symptoms of fibromyalgia. In other words, this drug is effectively used for the management of pain and seizures associated with various neurological disorders.
This medication is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medication is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: The initial dose may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation of treatment’). 2. Epilepsy Adults: The initial dose may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, it may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is mainly excreted unchanged by the kidneys. Its clearance is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In addition to the daily dose according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing instructions. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because safety and efficacy data are insufficient. Adolescents aged 12-17 years: Administration is not recommended because safety and efficacy data are insufficient.
This medication may increase the risk of suicidal ideation or behavior, so if changes in mood or behavior occur during treatment, consult a doctor immediately. People allergic to this medication's ingredients should not take it. Diabetic patients may experience weight gain while taking this medication, which may necessitate adjustment of blood sugar control medications. If symptoms of angioedema, such as swelling around the face or neck, occur, discontinue the medication immediately and inform a healthcare provider. Elderly patients may experience increased dizziness or drowsiness, so caution is especially advised when taking this medication for the first time. Temporary blurred vision or changes in vision may occur; consult a doctor if these symptoms arise. Suddenly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be decreased gradually according to a doctor's instructions. Patients with a history of substance abuse should be careful when taking this medication due to the potential for misuse or dependence. Patients with decreased kidney function may need dosage adjustments. Patients with severe heart disease should use this medication cautiously, as well as those at risk of respiratory depression. Using this medication in conjunction with opioid analgesics may enhance central nervous system depressant effects, so follow a doctor's guidance. In early pregnancy, it may affect the fetus, so pregnant women are advised not to take this drug; fertile women should use effective contraception. Lactating women should consult their doctor as this medication may be transmitted through breast milk, and breastfeeding may need to be discontinued. It's safest to avoid driving or operating machinery until dizziness or drowsiness subsides after taking this medication. If serious skin rashes or allergic reactions occur, discontinue the medication immediately and inform healthcare personnel. In cases of overdose, symptoms such as altered consciousness, drowsiness, and seizures may occur, necessitating immediate medical treatment. Keep this medication out of reach of children, and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 and 30 degrees Celsius. Proper storage will ensure the medication's efficacy is safely maintained.
White or pale yellow round tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Tablet · Prescription medication
Korean United Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.